Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03315585 Recruiting - Prostate Cancer Clinical Trials

The Efficacy and Safety of Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Focal Therapy

Start date: April 27, 2017
Phase: N/A
Study type: Interventional

This trial is studying the effects and safety in treating patients with local prostate cancer with a new IRE device called Composite Steep-pulse Treatment Apparatus. This new device could cause cell irreversible electroporation, which leading necrosis of tumor cells. It also has the ability to prevent nerve,vessel, urethral and capsule unnecessary injury beside the ablation area. Composite Steep-pulse Treatment Apparatus will be used in patients who pass inclusion/exclusion criteria. Safety, quality of life, and histopathological analysis of prostate speciem will be evaluated in each study patients.

NCT ID: NCT03313726 Recruiting - Prostate Cancer Clinical Trials

The Effect of ADT on PSMA-PET.

ADTPSMA
Start date: September 20, 2017
Phase: N/A
Study type: Interventional

Phase A: To describe and to determine the maximum standardised uptake values (SUV) in prostate specific membrane antigen positron emission tomography (PSMA-PET) before ADT and 7, 14 and 28 days after ADT. Phase B: To validate phase A results by comparing the PSMA-PET findings to histopathological analysis of regional lymph nodes acquired from radical prostatectomy specimens. PSMA-PET is done before ADT and at maximum SUV defined by the phase A.

NCT ID: NCT03310541 Recruiting - Breast Cancer Clinical Trials

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Start date: October 11, 2017
Phase: Phase 1
Study type: Interventional

This study will test the recommended dose of AZD5363 (recommended from a previous phase 1 study of the drug) in patients with specific AKT mutations. In patients who have ER positive breast cancer with an AKT mutation, they will also be receiving a standard breast cancer drug called fulvestrant that is given as an injection. In patients who have prostate cancer with an AKT mutation, they will also be receiving a standard prostate cancer drug called enzalutamide that is taken orally.

NCT ID: NCT03294122 Recruiting - Prostate Cancer Clinical Trials

Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer

MICROLEARNER
Start date: February 2, 2017
Phase: N/A
Study type: Observational

The main idea behind MICRO-LEARNER is to provide new insights about the response of healthy tissues to radiation by using information from the micro-environment obtained by biological measurements and imaging. This new knowledge will be included in current available predictive models of radio-induced toxicity, thus allowing to add unique biological characteristics of patients to dosimetry and treatment/clinical related variables. MICRO-LEARNER focuses on prostate cancer (PCa) and head-and-neck cancer (HNCa). For both cancers, radiotherapy is effectively used as curative treatment, in single modality or within a multidisciplinary approach including surgery (PCa) and/or chemotherapy (HNCa). Prediction and reduction of radio-induced side effects are becoming a priority: for PCa, high survival rates should be accompanied by a very low rate of moderate/severe toxicities; for HNCa, there is the need to tailor radiation dose according to disease recurrence risk profile. The shared aim of both cancers is to balance the improvement in outcome with a well-tolerated toxicity profile. Recent research indicates that the intestinal/salivary bacteria are strongly suspected of being very important in mediating the response to inflammation and lesions. Although their balance deeply changes during radiotherapy, studies done so far in the field of the microbiota-host relationship in radiotherapy have not addressed their role in insurgence of radiation toxicity. In this study, the investigators will assess how microbial populations evolve and how this influences the host and radiation induced toxicity in a significant number of patients. Moreover, the individual response at the tissue microstructure level, through analysis of images with advanced bioengineering techniques, will be determined. Results from this research, besides suggesting new ways to predict patients at risk of relevant side-effects, may also suggest possible treatments to change the baseline microbiota of patients at high risk or to modify it during therapy, in order to mitigate toxicity. Understanding the microbiota-radiotherapy interaction may thus lead to novel, effective and inexpensive ways of assessing and managing complications of cancer treatment.

NCT ID: NCT03290508 Recruiting - Prostate Cancer Clinical Trials

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

Start date: September 14, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.

NCT ID: NCT03290417 Recruiting - Prostate Cancer Clinical Trials

Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer

Start date: September 7, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to see if eating vitamin D, omega 3 and turmeric (curcumin) slows the growth of prostate cancer in men on active surveillance.

NCT ID: NCT03284151 Recruiting - Prostate Cancer Clinical Trials

Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma

Start date: January 2015
Phase: N/A
Study type: Observational [Patient Registry]

Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to quantify the delay between the focused treatment and the salvage procedure.

NCT ID: NCT03279250 Recruiting - Prostate Cancer Clinical Trials

Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence

Start date: October 13, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if adding abiraterone acetate and standard of care prednisone to the combination of apalutamide and a standard type of drug called an LHRH agonist can help to control prostate cancer when given before surgery. The safety of these drug combinations will also be studied. This is an investigational study. Apalutamide is not FDA approved or commercially available. It is currently being used for research purposes only. The combination of abiraterone acetate, LHRH agonists, and prednisone is FDA approved and commercially available for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drug combinations being used in this study are considered investigational. Up to 66 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03278197 Recruiting - Prostate Cancer Clinical Trials

Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients

ProDecA
Start date: January 2015
Phase: N/A
Study type: Interventional

Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients. The goal of the tool is to help patients to understand the treatments, and empower the patients to participate in the decision making process. The aim of this study is threefold: (A) user-testing and validation of the tool, by using a systematically development process compliant with the IPDAS (International Patients Decision Aids Standards) criteria (B) establish the impact of the tool on the decision making process; (C) identify barriers and facilitators for the implementation of shared decision making and the tool in clinical practice. The study covers 3 phases: 1. Development phase 1.1 Assess decisional needs of patients and clinicians. 1.2 Test patients' and clinicians' comprehensibility, acceptability and usability on the alpha-version of the tool. 1.3 Value clarification: Delphi study with former prostate cancer patients to determine the most important patient preferences and value clarification aspects the decision aid should include. 2. Implementation phase: Develop an implementation and dissemination plan for shared decision-making which is based on the evaluation of barriers and facilitators for the use of patient decision aid tools in clinical practice. 3. Evaluation phase: Establish the impact of on knowledge, decisional conflict and the shared decision-making process, as well as the extent to which clinicians involve patients in decision-making. A mixed method will be used. It comprises structured interviews combined with think aloud and questionnaires with stakeholders involved in the whole process of development, implementation and evaluation (patients, urologists, radiotherapists, nurses, general practitioners, patient organizations, and insurance companies).

NCT ID: NCT03276572 Recruiting - Prostate Cancer Clinical Trials

Phase I Trial of 225Ac−J591 in Patients With mCRPC

Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

This is an open−label, single−center Phase I dose escalation study designed to determine the dose−limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac−J591 in a single dose regimen.